ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2213 entries already.
The EU’s opt-out clause for GM cultivation has missed its goal to accelerate EU market approval of safety-assessed genetically modified crops whilst giving member states the option to opt out from cultivation for political reasons.
Three of six new meds to be approved in Europe are orphan drugs and have been backed by the European Medicines Agency (EMA) this month.
Good news for EMD Serono, the US arm of German Merck: It’s PD-L1 blocker avelumab is the first drug that received FDA approval to treat the rare skin cancer Merkel Cell Carcinoma (MCC).
With around 2,500 attendees, Barcelona hosted the most successful BIO Europe Spring conference in the history of the EBD’s partnering event. Southern Europe demonstrated its growth ambitions in the life sciences.
Scottish and Canadian researchers have identified a protein essential for the toxoplasmosis parasite to be transmitted. Targeting it might give rise to new treatments other parasitic diseases like malaria.
British inhaled anti-infectives specialist Pulmocide has bagged US$30.4m (€28.8m) from new and existing investors to bring its anti-RSV and anti-aspergillosis compounds into clinical testing.
The investment groups Q-Growth Fund and Biolty purchased the majority of the Valencian biotechnology company Institute of Genomic Medicine (Imegen) for €10m.
British Cell Medica has closed a 60£ (€68,8m) Series C financing to advance its pipeline of virus-specific Natural Killer T (NKT) cells in oncology and viral infection.
According to main investor Sofinnova Partners, the Euronext IPO of Avantium, the front runner in renewable chemistry, was oversubscribed multiple times resulting in a market capitalisation of €277m.
Transgene has started Phase II efficacy testing of its therapeutic cancer vaccine TG4010 and Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) in non-squamous non-small cell lung cancer (NSCLC).